Reconstitution of the NF1 GAP-related domain in NF1-deficient human Schwann cells

Biochemical and Biophysical Research Communications

Volumn 348, Issue 3, 2006, Pages 971-980

  Thomas, Stacey L ^a,b,c   Deadwyler, Gail D ^a   Tang, Jun ^a,b   Stubbs Jr , Evan B ^a,b   Muir, David ^d,e   Hiatt, Kelly K ^f   Clapp, D Wade ^f   De Vries, George H ^a,c  

^a Edward Hines Jr Hospital   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Morphology; MPNST; Neurofibroma; Neurofibromatosis; NF1; NF1 GRD; Proliferation; Ras; Schwann cell

Indexed keywords

GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; NEUROFIBROMIN; RAS PROTEIN; RETROVIRUS VECTOR;

ARTICLE; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; ENZYME RECONSTITUTION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MORPHOLOGY; NERVE SHEATH TUMOR; PERIPHERAL NERVE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCHWANN CELL;

BASE SEQUENCE; CELL LINE; CELLS, CULTURED; GTPASE-ACTIVATING PROTEINS; HUMANS; MOLECULAR SEQUENCE DATA; NEUROFIBROMIN 1; PROTEIN STRUCTURE, TERTIARY; RETROVIRIDAE; SCHWANN CELLS; TRANSDUCTION, GENETIC;

EID: 33747189245     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.07.159     Document Type: Article

References (63)

1. Xu G.F., O'Connell P., Viskochil D., Cawthon R., Robertson M., Culver M., Dunn D., Stevens J., Gesteland R., and White R. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 62 (1990) 599-608
2. Xu G.F., Lin B., Tanaka K., Dunn D., Wood D., Gesteland R., White R., Weiss R., and Tamanoi F. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell 63 (1990) 835-841
3. Ballester R., Marchuk D., Boguski M., Saulino A., Letcher R., Wigler M., and Collins F. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell 63 (1990) 851-859
4. Basu T.N., Gutmann D.H., Fletcher J.A., Glover T.W., Collins F.S., and Downward J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356 (1992) 713-715
5. DeClue J.E., Papageorge A.G., Fletcher J.A., Diehl S.R., Ratner N., Vass W.C., and Lowy D.R. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69 (1992) 265-273
6. Yu X., Chen S., Potter O.L., Murthy S.M., Li J., Pulcini J.M., Ohashi N., Winata T., Everett E.T., Ingram D., Clapp W.D., and Hock J.M. Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. Bone 36 (2005) 793-802
7. Dasgupta B., and Gutmann D.H. Neurofibromin regulates neural stem cell proliferation, survival, and astroglial differentiation in vitro and in vivo. J. Neurosci. 25 (2005) 5584-5594
8. Bennett M.R., Rizvi T.A., Karyala S., McKinnon R.D., and Ratner N. Aberrant growth and differentiation of oligodendrocyte progenitors in neurofibromatosis type 1 mutants. J. Neurosci. 23 (2003) 7207-7217
9. Ingram D.A., Yang F.C., Travers J.B., Wenning M.J., Hiatt K., New S., Hood A., Shannon K., Williams D.A., and Clapp D.W. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J. Exp. Med. 191 (2000) 181-188
10. Gutmann D.H., Loehr A., Zhang Y., Kim J., Henkemeyer M., and Cashen A. Haploinsufficiency for the neurofibromatosis 1 (NF1) tumor suppressor results in increased astrocyte proliferation. Oncogene 18 (1999) 4450-4459
11. Zhang Y.Y., Vik T.A., Ryder J.W., Srour E.F., Jacks T., Shannon K., and Clapp D.W. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J. Exp. Med. 187 (1998) 1893-1902
12. Bollag G., Clapp D.W., Shih S., Adler F., Zhang Y.Y., Thompson P., Lange B.J., Freedman M.H., McCormick F., Jacks T., and Shannon K. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat. Genet. 12 (1996) 144-148
13. Largaespada D.A., Brannan C.I., Jenkins N.A., and Copeland N.G. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat. Genet. 12 (1996) 137-143
14. Rosenbaum T., Boissy Y.L., Kombrinck K., Brannan C.I., Jenkins N.A., Copeland N.G., and Ratner N. Neurofibromin-deficient fibroblasts fail to form perineurium in vitro. Development 121 (1995) 3583-3592
15. Kadono T., Soma Y., Takehara K., Nakagawa H., Ishibashi Y., and Kikuchi K. The growth regulation of neurofibroma cells in neurofibromatosis type-1: increased responses to PDGF-BB and TGF-beta 1. Biochem. Biophys. Res. Commun. 198 (1994) 827-834
16. Kim H.A., Rosenbaum T., Marchionni M.A., Ratner N., and DeClue J.E. Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes. Oncogene 11 (1995) 325-335
17. Kim H.A., Ling B., and Ratner N. Nf1-deficient mouse Schwann cells are angiogenic and invasive and can be induced to hyperproliferate: reversion of some phenotypes by an inhibitor of farnesyl protein transferase. Mol. Cell Biol. 17 (1997) 862-872
18. Wu M., Wallace M.R., and Muir D. Tumorigenic properties of neurofibromin-deficient Schwann cells in culture and as syngrafts in Nf1 knockout mice. J. Neurosci. Res. 82 (2005) 357-367
19. Badache A., and De Vries G.H. Neurofibrosarcoma-derived Schwann cells overexpress platelet-derived growth factor (PDGF) receptors and are induced to proliferate by PDGF BB. J. Cell Physiol. 177 (1998) 334-342
20. Badache A., Muja N., and De Vries G.H. Expression of Kit in neurofibromin-deficient human Schwann cells: role in Schwann cell hyperplasia associated with type 1 neurofibromatosis. Oncogene 17 (1998) 795-800
21. Muir D., Neubauer D., Lim I.T., Yachnis A.T., and Wallace M.R. Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells. Am. J. Pathol. 158 (2001) 501-513
22. Mashour G.A., Ratner N., Khan G.A., Wang H.L., Martuza R.L., and Kurtz A. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene 20 (2001) 97-105
23. Lee J.K., Choi B., Sobel R.A., Chiocca E.A., and Martuza R.L. Inhibition of growth and angiogenesis of human neurofibrosarcoma by heparin and hydrocortisone. J. Neurosurg. 73 (1990) 429-435
24. Angelov L., Salhia B., Roncari L., McMahon G., and Guha A. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Res. 59 (1999) 5536-5541
25. Sheela S., Riccardi V.M., and Ratner N. Angiogenic and invasive properties of neurofibroma Schwann cells. J. Cell Biol. 111 (1990) 645-653
26. Wu M., Wallace M.R., and Muir D. Nf1 haploinsufficiency augments angiogenesis. Oncogene 25 (2006) 2297-2303
27. Hiatt K.K., Ingram D.A., Zhang Y., Bollag G., and Clapp D.W. Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1-/- cells. J. Biol. Chem. 276 (2001) 7240-7245
28. Li Y., and White R. Suppression of a human colon cancer cell line by introduction of an exogenous NF1 gene. Cancer Res. 56 (1996) 2872-2876
29. Nur-E-Kamal M.S., Varga M., and Maruta H. The GTPase-activating NF1 fragment of 91 amino acids reverses v-Ha-Ras-induced malignant phenotype. J. Biol. Chem. 268 (1993) 22331-22337
30. Casella G.T., Bunge R.P., and Wood P.M. Improved method for harvesting human Schwann cells from mature peripheral nerve and expansion in vitro. Glia 17 (1996) 327-338
31. Clive D.R., Lopez T.J., and DeVries G.H. Quantitation of changes in P0 mRNA by polymerase chain reaction in primary cultured Schwann cells stimulated by axolemma-enriched fraction. J. Neurosci. Methods 81 (1998) 25-34
32. Sudhir K., Hashimura K., Bobik A., Dilley R.J., Jennings G.L., and Little P.J. Mechanical strain stimulates a mitogenic response in coronary vascular smooth muscle cells via release of basic fibroblast growth factor. Am. J. Hypertens. 14 (2001) 1128-1134
33. Zohn I.M., Campbell S.L., Khosravi-Far R., Rossman K.L., and Der C.J. Rho family proteins and Ras transformation: the RHOad less traveled gets congested. Oncogene 17 (1998) 1415-1438
34. The I., Hannigan G.E., Cowley G.S., Reginald S., Zhong Y., Gusella J.F., Hariharan I.K., and Bernards A. Rescue of a Drosophila NF1 mutant phenotype by protein kinase A. Science 276 (1997) 791-794
35. Guo H.F., The I., Hannan F., Bernards A., and Zhong Y. Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides. Science 276 (1997) 795-798
36. Kim H.A., Ratner N., Roberts T.M., and Stiles C.D. Schwann cell proliferative responses to cAMP and Nf1 are mediated by cyclin D1. J. Neurosci. 21 (2001) 1110-1116
37. Tong J., Hannan F., Zhu Y., Bernards A., and Zhong Y. Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat. Neurosci. 5 (2002) 95-96
38. Dasgupta B., Dugan L.L., and Gutmann D.H. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J. Neurosci. 23 (2003) 8949-8954
39. Gregory P.E., Gutmann D.H., Mitchell A., Park S., Boguski M., Jacks T., Wood D.L., Jove R., and Collins F.S. Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules. Somat. Cell Mol. Genet. 19 (1993) 265-274
40. Bollag G., McCormick F., and Clark R. Characterization of full-length neurofibromin: tubulin inhibits Ras GAP activity. EMBO J. 12 (1993) 1923-1927
41. Xu H., and Gutmann D.H. Mutations in the GAP-related domain impair the ability of neurofibromin to associate with microtubules. Brain Res. 759 (1997) 149-152
42. Li C., Cheng Y., Gutmann D.A., and Mangoura D. Differential localization of the neurofibromatosis 1 (NF1) gene product, neurofibromin, with the F-actin or microtubule cytoskeleton during differentiation of telencephalic neurons. Brain Res. Dev. Brain Res. 130 (2001) 231-248
43. Koivunen J., Yla-Outinen H., Korkiamaki T., Karvonen S.L., Poyhonen M., Laato M., Karvonen J., Peltonen S., and Peltonen J. New function for NF1 tumor suppressor. J. Invest. Dermatol. 114 (2000) 473-479
44. Malminen M., Peltonen S., Koivunen J., and Peltonen J. Functional expression of NF1 tumor suppressor protein: association with keratin intermediate filaments during the early development of human epidermis. BMC Dermatol. 2 (2002) 10
45. Legius E., Dierick H., Wu R., Hall B.K., Marynen P., Cassiman J.J., and Glover T.W. TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer 10 (1994) 250-255
46. Menon A.G., Anderson K.M., Riccardi V.M., Chung R.Y., Whaley J.M., Yandell D.W., Farmer G.E., Freiman R.N., Lee J.K., Li F.P., et al. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc. Natl. Acad. Sci. USA 87 (1990) 5435-5439
47. Mukhopadhyay D., Tsiokas L., and Sukhatme V.P. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 55 (1995) 6161-6165
48. Volpert O.V., Stellmach V., and Bouck N. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res. Treat 36 (1995) 119-126
49. Van Meir E.G., Polverini P.J., Chazin V.R., Su Huang H.J., de Tribolet N., and Cavenee W.K. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat. Genet 8 (1994) 171-176
50. Dameron K.M., Volpert O.V., Tainsky M.A., and Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265 (1994) 1582-1584
51. Kourea H.P., Orlow I., Scheithauer B.W., Cordon-Cardo C., and Woodruff J.M. Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am. J. Pathol. 155 (1999) 1855-1860
52. Berner J.M., Sorlie T., Mertens F., Henriksen J., Saeter G., Mandahl N., Brogger A., Myklebost O., and Lothe R.A. Chromosome band 9p21 is frequently altered in malignant peripheral nerve sheath tumors: studies of CDKN2A and other genes of the pRB pathway. Genes Chromosomes Cancer 26 (1999) 151-160
53. Nielsen G.P., Stemmer-Rachamimov A.O., Ino Y., Moller M.B., Rosenberg A.E., and Louis D.N. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am. J. Pathol. 155 (1999) 1879-1884
54. Perrone F., Tabano S., Colombo F., Dagrada G., Birindelli S., Gronchi A., Colecchia M., Pierotti M.A., and Pilotti S. p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Clin. Cancer Res. 9 (2003) 4132-4138
55. Kamijo T., Weber J.D., Zambetti G., Zindy F., Roussel M.F., and Sherr C.J. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA 95 (1998) 8292-8297
56. Zhang Y., Xiong Y., and Yarbrough W.G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 92 (1998) 725-734
57. Pomerantz J., Schreiber-Agus N., Liegeois N.J., Silverman A., Alland L., Chin L., Potes J., Chen K., Orlow I., Lee H.W., Cordon-Cardo C., and DePinho R.A. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92 (1998) 713-723
58. Hannon G.J., and Beach D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371 (1994) 257-261
59. Serrano M., Hannon G.J., and Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366 (1993) 704-707
60. Harada H., Nakagawa K., Iwata S., Saito M., Kumon Y., Sakaki S., Sato K., and Hamada K. Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. Cancer Res. 59 (1999) 3783-3789
61. Miki K., Shimizu E., Yano S., Tani K., and Sone S. Demethylation by 5-aza-2′-deoxycytidine (5-azadC) of p16INK4A gene results in downregulation of vascular endothelial growth factor expression in human lung cancer cell lines. Oncol Res. 12 (2000) 335-342
62. Gibson S.L., Dai C.Y., Lee H.W., DePinho R.A., Gee M.S., Lee W.M., Furth E.E., Brensinger C., and Enders G.H. Inhibition of colon tumor progression and angiogenesis by the Ink4a/Arf locus. Cancer Res. 63 (2003) 742-746
63. Mawrin C., Kirches E., Boltze C., Dietzmann K., Roessner A., and Schneider-Stock R. Immunohistochemical and molecular analysis of p53, RB, and PTEN in malignant peripheral nerve sheath tumors. Virchows Arch. 440 (2002) 610-615